Filing Flows › UroGen Pharma (URGN) › Recalls, complaints & regulation
UroGen Pharma (URGN): clinical trials
UroGen Pharma (URGN) beyond its filings: 4 active clinical trials.
UroGen Pharma's latest quarter
UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does UroGen Pharma have?
4 active studies on ClinicalTrials.gov, 2 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.